Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
643 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06163040 | A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan | completed | — | 7 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 31, 2025 | clinicaltrials |
| NCT04026412 | A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery(CheckMate73L) | completed | Phase 3 | 925 | Bristol-Myers SquibbINDUSTRY |
| 27 |
| Jul 24, 2025 |
| clinicaltrials |
| NCT07079644 | Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database | completed | — | 678 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06024174 | A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors | terminated | Phase 1 / Phase 2 | 5 | Bristol-Myers SquibbINDUSTRY | 5 | Jul 22, 2025 | clinicaltrials |
| NCT02990611 | Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy(NICO) | completed | — | 1,087 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT04513522 | A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India(CheckMate 7C9) | completed | Phase 4 | 101 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT04050761 | A Study of Nivolumab in Patients With Head and Neck Cancer.(ProNiHN) | completed | — | 502 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT05605782 | A Post-Authorization, Long-term Study of Ozanimod Real-world Safety(ORION) | active not recruiting | — | 9,000 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 26, 2025 | clinicaltrials |
| NCT02667587 | An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)(CheckMate548) | completed | Phase 3 | 716 | Bristol-Myers SquibbINDUSTRY | 19 | Jun 18, 2025 | clinicaltrials |
| NCT03114163 | Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy | completed | — | 485 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07024862 | Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy | active not recruiting | — | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT05625412 | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | completed | Phase 1 | 70 | Bristol-Myers SquibbINDUSTRY | 9 | Jun 13, 2025 | clinicaltrials |
| NCT04100018 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer(CheckMate 7DX) | completed | Phase 3 | 1,030 | Bristol-Myers SquibbINDUSTRY | 28 | Jun 12, 2025 | clinicaltrials |
| NCT05888831 | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Bristol-Myers SquibbINDUSTRY | 6 | Jun 11, 2025 | clinicaltrials |
| NCT05169684 | A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer | terminated | Phase 2 | 10 | Bristol-Myers SquibbINDUSTRY | 3 | Jun 10, 2025 | clinicaltrials |
| NCT06421311 | Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France(URADJ) | terminated | — | 176 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06422247 | Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy | completed | — | 307 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06499298 | Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer | completed | — | 64 | Bristol-Myers SquibbINDUSTRY | 1 | May 31, 2025 | clinicaltrials |
| NCT01844505 | Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | completed | Phase 3 | 945 | Bristol-Myers SquibbINDUSTRY | 22 | May 21, 2025 | clinicaltrials |
| NCT06952465 | A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis | active not recruiting | — | 2,000 | Bristol-Myers SquibbINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT02388906 | Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma(CheckMate 238) | completed | Phase 3 | 906 | Bristol-Myers SquibbINDUSTRY | 25 | Apr 24, 2025 | clinicaltrials |
| NCT03110107 | First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 376 | Bristol-Myers SquibbINDUSTRY | 17 | Apr 24, 2025 | clinicaltrials |
| NCT02913313 | A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 101 | Bristol-Myers SquibbINDUSTRY | 8 | Apr 20, 2025 | clinicaltrials |
| NCT06094296 | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 1 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 16, 2025 | clinicaltrials |
| NCT04943900 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | completed | Phase 1 | 67 | Bristol-Myers SquibbINDUSTRY | 7 | Apr 9, 2025 | clinicaltrials |
| NCT02017717 | A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients(CheckMate 143) | completed | Phase 3 | 529 | Bristol-Myers SquibbINDUSTRY | 12 | Apr 4, 2025 | clinicaltrials |
| NCT03635983 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma | completed | Phase 3 | 783 | Bristol-Myers SquibbINDUSTRY | 27 | Apr 1, 2025 | clinicaltrials |
| NCT03200977 | Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab | completed | — | 95 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05543629 | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 36 | Bristol-Myers SquibbINDUSTRY | 5 | Mar 18, 2025 | clinicaltrials |
| NCT01420770 | Phase 2 Study of SAR302503 in Patients With Myelofibrosis | completed | Phase 2 | 30 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT01420783 | Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia | completed | Phase 2 | 81 | Bristol-Myers SquibbINDUSTRY | 9 | Mar 5, 2025 | clinicaltrials |
| NCT01585623 | Drug Interaction Study of SAR302503 in Patients With Solid Tumor | completed | Phase 1 | 16 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT01836705 | Effect of SAR302503 on ECG Activity in Patients With Solid Tumors | completed | Phase 1 | 60 | Bristol-Myers SquibbINDUSTRY | 2 | Mar 5, 2025 | clinicaltrials |
| NCT05165264 | A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer(INGA) | active not recruiting | — | 600 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT05297565 | A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection(CheckMate-6GE) | completed | Phase 3 | 14 | Bristol-Myers SquibbINDUSTRY | 7 | Feb 27, 2025 | clinicaltrials |
| NCT06788639 | A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting | recruiting | — | 300 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06788652 | A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting | recruiting | — | 300 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06794268 | A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting | recruiting | — | 300 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03956680 | An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers | completed | Phase 1 | 54 | Bristol-Myers SquibbINDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 3 | 743 | Bristol-Myers SquibbINDUSTRY | 22 | Feb 17, 2025 | clinicaltrials |
| NCT02966548 | Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04043975 | A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan | completed | — | 286 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT02927769 | A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment(CheckMate 744) | completed | Phase 2 | 72 | Bristol-Myers SquibbINDUSTRY | 11 | Feb 10, 2025 | clinicaltrials |
| NCT03662659 | An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers | completed | Phase 2 | 274 | Bristol-Myers SquibbINDUSTRY | 17 | Feb 5, 2025 | clinicaltrials |
| NCT04146324 | An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia | completed | — | 150 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 24, 2025 | clinicaltrials |
| NCT05742867 | A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder(SNUGGLE) | completed | — | 115 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06425198 | Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment | completed | Phase 1 | 37 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
| NCT05324436 | A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM) | completed | — | 75 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04109066 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer(CheckMate 7FL) | completed | Phase 3 | 521 | Bristol-Myers SquibbINDUSTRY | 32 | Jan 8, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials